<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jaeger BC</submitter><funding>NICHD NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>94-101</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9259065</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>40(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The 2017 American College of Cardiology/American Heart Association blood pressure (BP) guideline recommends using 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk to guide decisions to initiate antihypertensive medication.&lt;h4>Methods&lt;/h4>We included adults aged 40-79 years from the National Health and Nutrition Examination Survey 2013-2018 (n = 8803). We computed 10-year predicted ASCVD risk using the Pooled Cohort risk equations. Clinical CVD was self-reported. Analyses were conducted overall and among those with stage 1 hypertension, defined by a mean SBP of 130-139 mmHg or DBP of 80-89 mmHg. In subgroups defined by diabetes, chronic kidney disease (CKD), and age at least 65 years, we estimated the proportion of United States adults with high ASCVD</pubmed_abstract><journal>Journal of hypertension</journal><pubmed_title>Predicted cardiovascular risk for United States adults with diabetes, chronic kidney disease, and at least 65 years of age.</pubmed_title><pmcid>PMC9259065</pmcid><funding_grant_id>K12 HD043451</funding_grant_id><funding_grant_id>P20 GM109036</funding_grant_id><funding_grant_id>R01 HL144773</funding_grant_id><funding_grant_id>R01 HL139716</funding_grant_id><pubmed_authors>Hardy ST</pubmed_authors><pubmed_authors>Muntner P</pubmed_authors><pubmed_authors>Sakhuja S</pubmed_authors><pubmed_authors>Akinyelure OP</pubmed_authors><pubmed_authors>Whelton PK</pubmed_authors><pubmed_authors>Jaeger BC</pubmed_authors><pubmed_authors>Bundy JD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predicted cardiovascular risk for United States adults with diabetes, chronic kidney disease, and at least 65 years of age.</name><description>&lt;h4>Background&lt;/h4>The 2017 American College of Cardiology/American Heart Association blood pressure (BP) guideline recommends using 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk to guide decisions to initiate antihypertensive medication.&lt;h4>Methods&lt;/h4>We included adults aged 40-79 years from the National Health and Nutrition Examination Survey 2013-2018 (n = 8803). We computed 10-year predicted ASCVD risk using the Pooled Cohort risk equations. Clinical CVD was self-reported. Analyses were conducted overall and among those with stage 1 hypertension, defined by a mean SBP of 130-139 mmHg or DBP of 80-89 mmHg. In subgroups defined by diabetes, chronic kidney disease (CKD), and age at least 65 years, we estimated the proportion of United States adults with high ASCVD</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-26T00:23:14.679Z</modification><creation>2025-04-06T09:44:26.8Z</creation></dates><accession>S-EPMC9259065</accession><cross_references><pubmed>34420013</pubmed><doi>10.1097/HJH.0000000000002982</doi><doi>10.1097/hjh.0000000000002982</doi></cross_references></HashMap>